Ascend BioVentures
Ascend BioVentures is a pharmaceutical accelerator company dedicated to shepherding promising drug candidates through the riskiest, early stages of development. They focus on identifying innovative therapeutics and launching companies in preclinical drug development, benefiting from experienced management, scientists, consultants, and investors. They operate with a virtual model, leveraging partnerships with CROs and other resources to increase efficiency and reduce costs, while maintaining a focus on science and innovation.
Industries
Nr. of Employees
small (1-50)
Ascend BioVentures
Oklahoma City, Oklahoma, United States, North America
Products
Oral therapeutic candidate for protection of residual hearing
An oral candidate developed to protect residual hearing in cochlear implant patients; completed Phase 1 safety/pharmacokinetic studies and planned progression to Phase 2 in collaboration with a development partner.
Preclinical regenerative siRNA program for auditory sensory cell restoration
Preclinical program using siRNA approaches to regenerate cochlear sensory hair cells with demonstrated restoration of auditory function in animal models.
Multivalent Clostridioides difficile vaccine candidate
Vaccine program intended to protect against multiple hypervirulent strains and reduce relapse; listed as part of the accelerator portfolio.
Oral therapeutic candidate for protection of residual hearing
An oral candidate developed to protect residual hearing in cochlear implant patients; completed Phase 1 safety/pharmacokinetic studies and planned progression to Phase 2 in collaboration with a development partner.
Preclinical regenerative siRNA program for auditory sensory cell restoration
Preclinical program using siRNA approaches to regenerate cochlear sensory hair cells with demonstrated restoration of auditory function in animal models.
Multivalent Clostridioides difficile vaccine candidate
Vaccine program intended to protect against multiple hypervirulent strains and reduce relapse; listed as part of the accelerator portfolio.
Services
Identification, technical vetting, and launch support for early‑stage therapeutic programs and spin‑out companies focused on preclinical development.
Project management, clinical operations coordination, data management, and biostatistics support for clinical trials.
Selection and management of CROs for efficacy, safety, formulation, and specialized in vivo studies including biosafety facility work.
Use of partner organization administrative and physical resources to support company operations and lower infrastructure costs.
Identification, technical vetting, and launch support for early‑stage therapeutic programs and spin‑out companies focused on preclinical development.
Project management, clinical operations coordination, data management, and biostatistics support for clinical trials.
Selection and management of CROs for efficacy, safety, formulation, and specialized in vivo studies including biosafety facility work.
Use of partner organization administrative and physical resources to support company operations and lower infrastructure costs.
Expertise Areas
- Preclinical development and translational research
- Clinical operations and early‑phase studies
- CRO management and vendor engagement
- Virtual drug development and distributed program coordination
Key Technologies
- In vivo animal models (including specialized genetic and infectious‑disease models)
- GLP toxicology studies
- Pharmacokinetic (PK) studies
- siRNA therapeutics
News & Updates
Summary of the Alliance for Artificial Intelligence in Healthcare’s Second Annual Members Meeting at Genentech, San Francisco.
Discussion on the challenges of having a physical lab and how CROs support pharmaceutical startups in drug development.
Exploration of virtual drug development models and their advantages for startups.
Description of how Ascend BioVentures operates virtually, with teams in different locations and remote lab work.
Discussion on the benefits and challenges of virtual drug development models for startups.
Summary of the Alliance for Artificial Intelligence in Healthcare’s Second Annual Members Meeting at Genentech, San Francisco.
Discussion on the challenges of having a physical lab and how CROs support pharmaceutical startups in drug development.
Exploration of virtual drug development models and their advantages for startups.
Description of how Ascend BioVentures operates virtually, with teams in different locations and remote lab work.
Discussion on the benefits and challenges of virtual drug development models for startups.